Figure_6.tif (2.67 MB)

AMD3100 prevented severe pulmonary arterial hypertension (PAH) in the SU5416/chronic hypoxia (SuHx) model.

figure

posted on 2014-02-24, 03:32 authored by Daniela Farkas, Donatas Kraskauskas, Jennifer I. Drake, Aysar A. Alhussaini, Vita Kraskauskiene, Harm J. Bogaard, Carlyne D. Cool, Norbert F. Voelkel, Laszlo Farkas

(A) Representative von Willebrand Factor (vWF) immunohistochemistry indicates the occlusion of pulmonary arteries (arrows). These images demonstrate that treatment with the CXC chemokine receptor 4 inhibitor AMD3100 only partially prevented the obliteration of pulmonary arteries. Counterstaining: Mayer’s Hematoxylin. Magnification: 100×. Scale bar: 100 µm. (B) Reduced right ventricular systolic pressure (RVSP) and (C) decreased right ventricle (RV)/(left ventricle [LV]+Septum) ratio. (D) Reduced pulmonary arterial muscularization (external diameter [ED] <100 µm) was detected after AMD3100 treatment. (E-F) The degree of obliteration of pulmonary arteries in AMD3100-treated SuHx animals was partially reduced for small (E) (25 µmP<0.05, ** P<0.01, *** P<0.0001.